Figure 2 Effect of anakinra treatment on circulating mediators of patients with lower respiratory tract infection by SARS-CoV-2

Concentrations of A) suPAR (soluble urokinase plasminogen activator receptor); B) the absolute lymphocyte count; C) interleukin (IL)-6; and D) sCD163 of patients under standard-of-care treatment (SOC, blue colour) and of patients under SOC treatment with anakinra (red colour) at baseline (day of hospital admission) and day 7 of follow-up are shown. The concentrations of sIL-2R on day 7 are provided in panel E. The number of patients in each group is provided inside the bars.

Lines refer to median values. Comparisons between different groups were performed by the Mann-Whitney U test and within the same group by the Wilcoxon test. Statistical comparisons: ns, non-significant; *P< 0.05; **P<0.01; ***P<0.0001 The correlation of the IL-10/IL-6 ratio with the absolute change of the SOFA (sequential organ failure assessment) score on day 14 from the baseline is also shown (panel F). The Spearman rank of order correlation co-efficient and the P-value of the correlation is provided.